



Maternal urinary phthalate metabolites in relation to gestational diabetes and glucose intolerance during pregnancy

Rachel M. Shaffer^{a,*}, Kelly K. Ferguson^b, Lianne Sheppard^{a,c}, Tamarra James-Todd^{d,e}, Samantha Butts^f, Suchitra Chandrasekaran^g, Shanna H. Swan^h, Emily S. Barrettⁱ, Ruby Nguyen^j, Nicole Bush^k, Thomas F. McElrath^l, Sheela Sathyanarayana^{a,m}, and the TIDES Study team

^a Department of Environmental and Occupational Health Sciences, University of Washington, Seattle, WA, USA

^b Epidemiology Branch, Intramural Research Program, National Institute of Environmental Health Sciences, Research Triangle Park, NC, USA

^c Department of Biostatistics, University of Washington, Seattle, WA, USA

^d Departments of Environmental Health and Epidemiology, Harvard School of Public Health, Boston, MA, USA

^e Division of Women's Health, Department of Medicine, Connors Center for Women's Health and Gender Biology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA

^f Department of Obstetrics and Gynecology, University of Pennsylvania, Philadelphia, PA, USA

^g Department of Obstetrics and Gynecology, Division of Maternal Fetal Medicine, University of Washington, Seattle, WA, USA

^h Department of Environmental Medicine and Public Health, Icahn School of Medicine at Mount Sinai, New York, NY, USA

ⁱ Department of Epidemiology, Environmental and Occupational Health Sciences Institute, Rutgers School of Public Health, Piscataway, NJ, USA

^j Department of Epidemiology and Community Health, University of Minnesota, Minneapolis, MN, USA

^k Department of Psychiatry and Pediatrics, University of California San Francisco, San Francisco, CA, USA

^l Division of Maternal-Fetal Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA

^m Seattle Children's Research Institute, Seattle, WA, USA

ARTICLE INFO

Handling Editor: Zorana Jovanovic Andersen

Keywords:

Gestational diabetes
Impaired glucose intolerance
Blood glucose
Phthalates
Endocrine disruptors
Pregnancy

ABSTRACT

Background: Phthalates are common plasticizer chemicals that have been linked to glucose intolerance in the general population, but there is only limited research on their association with gestational diabetes (GDM).

Objective: We evaluated the association between 11 urinary phthalate metabolites and GDM, impaired glucose tolerance (IGT), and continuous blood glucose concentration during pregnancy in The Infant Development and Environment Study (TIDES). Based on prior study results, our primary analyses focused on monoethyl phthalate (MEP) in relation to our outcomes of interest.

Study design: We used multi-variable logistic regression to examine the odds of GDM and IGT in relation to an interquartile-range (IQR) increase in natural log (ln)-transformed, specific gravity (SG)-adjusted first trimester (T1) and average of T1 and third trimester (T3) (“T1T3avg”) phthalate metabolite concentrations. We fit linear regression models to examine the percent change in blood glucose per IQR increase in ln-transformed, SG-adjusted T1 and T1T3avg phthalates. In sensitivity analyses, we examined interactions between exposure and race. We adjusted for maternal age, maternal body mass index, study center, race/ethnicity, parity, and gestational age at glucose testing. **Results:** In our sample of 705 pregnant women, we observed 60 cases of GDM, 90 cases of IGT, and an average GLT blood glucose of 113.6 ± 27.7 mg/dL. In our primary analysis, T1T3avg MEP was positively associated with GDM ([OR (95% CI) per IQR increase] T1T3avg MEP: 1.61 (1.10, 2.36)). In secondary analyses, most other phthalates were not found to be related to study outcomes, though some associations were noted. Sensitivity analyses indicated possible strong race-specific associations in Asians, though these results are based on a small sample size ($n = 35$).

Conclusion: In alignment with our *a priori* selection, we documented an association between T1T3avg MEP and GDM. Additional phthalate metabolites were also found to be linked to glucose intolerance, with possible stronger associations in certain racial/ethnic subgroups. Given the prevalence of phthalate exposures and the growing evidence of associations with metabolic outcomes, future studies should continue to examine this question in diverse cohorts of pregnant women, particularly in those who may be at higher risk for GDM and IGT.

* Corresponding author.

E-mail address: rms14@uw.edu (R.M. Shaffer).

<https://doi.org/10.1016/j.envint.2018.12.021>

Received 26 October 2018; Received in revised form 11 December 2018; Accepted 11 December 2018

Available online 07 January 2019

0160-4120/© 2019 Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

1. Introduction

Gestational diabetes mellitus (GDM) is glucose intolerance that develops during pregnancy (American Diabetes Association, 2012). In GDM, there is insufficient insulin released from the beta cells and decreased skeletal muscle glucose uptake, resulting in maternal hyperglycemia. Incidence of GDM in the United States has increased dramatically in the past twenty years, (Albrecht et al., 2010; Bardenheier et al., 2015; Thorpe et al., 2005) partially attributed to improved detection. GDM is now detected in 8–9% percent of pregnancies in the U.S., though estimates vary based on ethnicity and diagnostic criteria (Caughey et al., 2010; Coustan et al., 2010; DeSisto et al., 2014; Ehrlich et al., 2016; Reece, 2010). Risk factors include prior GDM (Holmes et al., 2010; Kim et al., 2007), previous large for gestational age (LGA) infant (Simmons et al., 2009), family history of GDM or type 2 diabetes mellitus (T2DM) (Ben-Haroush et al., 2003), pre-pregnancy obesity (Chu et al., 2007; Torloni et al., 2009), nonwhite race/ethnicity (Berkowitz et al., 1992), high gestational weight gain in early pregnancy (Morisset et al., 2011), and increased maternal age (Lao et al., 2006; Reece, 2010). GDM is associated with health consequences for the mother and child, but recent research suggests that elevated maternal blood glucose even without overt GDM diagnosis, such as in impaired glucose tolerance (IGT), is also associated with adverse fetal and maternal outcomes (The HAPO Study Cooperative Research Group, 2008).

The etiology of beta cell dysfunction and related pathologies in GDM is not well understood. Possible contributing factors and mediators include: alterations in inflammatory signaling, which can affect the insulin receptor and glucose transporters (Winkler et al., 2002); changes in expression of peroxisome proliferator activated receptors (PPARs) (Catalano et al., 2002); and oxidative stress (Chen and Scholl, 2005; Coughlan et al., 2004; Lappas et al., 2011). Some women (< 10% of GDM cases) have circulating antibodies to islet cells or key cellular enzymes, similar to those in type 1 diabetes (T1DM) (Catalano et al., 1990). Increasing evidence suggests that chemical exposure may also play a role in metabolic dysregulation in pregnancy, perhaps through the pathways described above (Ehrlich et al., 2016).

Phthalates are chemicals utilized in numerous consumer applications, including plastics, personal care products, food packaging, and medical devices (Sathyanarayana, 2008; Schettler, 2006). Because they are not bound to products, phthalates can easily migrate into air, dust, and food. Exposure occurs through ingestion, inhalation, and/or dermal contact (Schettler, 2006). Phthalates are known endocrine disruptors (National Research Council, 2008), and growing evidence indicates a link to metabolic dysfunction, including obesity and diabetes (Hatch et al., 2008; James-Todd et al., 2012; Stahlhut et al., 2007).

Published studies on the relationship between phthalates and gestational glucose intolerance are limited. The only cohort study ($n = 1274$) to examine GDM diagnosis in relation to phthalate exposure found no evidence of increased risk (Shapiro et al., 2015). However, other studies have documented associations between phthalate exposure and both increases and decreases in blood glucose concentration and/or risk factors for GDM (Fisher et al., 2018; James-Todd et al., 2018; James-Todd et al., 2016; Robledo et al., 2015).

To further address this question, we utilized data from The Infant Development and Environment Study (TIDES) to investigate the associations of urinary phthalate metabolite concentrations with GDM, IGT, and continuous blood glucose. Based on results from prior studies (James-Todd et al., 2018; James-Todd et al., 2016), our primary analytical hypothesis was that concentrations of monoethyl phthalate (MEP) would be higher among mothers with GDM compared to those who did not develop GDM. Secondary analyses considered additional individual phthalate metabolites and one weighted summary score of di-2-ethylhexyl phthalate (DEHP) metabolites. In sensitivity analyses, we evaluated race-specific associations and non-linear associations. Our study improves and expands upon previous related analyses by

examining a large population from four distinct geographic regions, utilizing more than one urinary measure of phthalate exposure, and including subclinical measures (such as continuous glucose and IGT) based on medical records in addition to clinical diagnosis of GDM.

2. Materials and methods

2.1. Study design

From 2010 to 2012, TIDES recruited first trimester (T1) pregnant women at the University of California San Francisco (UCSF), University of Minnesota (UMN), University of Rochester Medical Center (URMC), and Seattle Children's Hospital/University of Washington (SCH/UW). Eligibility criteria included: < 13 weeks pregnant, English speaking, ≥ 18 years of age, no severe threat to pregnancy, and intention to deliver at a study hospital. After providing informed consent, participants completed questionnaires and provided urine samples during each trimester of pregnancy. Glucose tolerance test results and other data were abstracted by staff at each site from birth and medical records, with one in ten records undergoing double abstraction for quality control. This study was approved by the UW Institutional Review Board (IRB) (Study ID: #00002643).

The overall TIDES cohort includes 753 women, but this analysis is limited to 705 women who completed a T1 questionnaire, had T1 phthalate data, and underwent a glucose load test (GLT). Because a GLT is only administered to pregnant women without prior diabetes, our study is limited to individuals without previous diabetes diagnoses.

2.2. Exposure assessment

Data from T1 and third trimester (T3) urine samples were available for this analysis. T3 collection occurred concurrent with or after GDM screening. Samples were collected in sterile, phthalate-free specimen cups, transferred to cryovials, and stored at -80°C until analysis. Specific gravity (SG) was measured with a handheld refractometer at the time of urine collection. Phthalate metabolite analyses were carried out at two laboratories. Most samples were analyzed at the National Center for Environmental Health, Centers for Disease Control and Prevention (CDC). This process involved enzymatic deconjugation of phthalate metabolites from glucuronidated form, automated online solid phase extraction, separation with high performance liquid chromatography (HPLC), and detection by isotope-dilution tandem mass spectrometry (Silva et al., 2007). A subset of samples were analyzed at the University of Washington (UW) with a modified version of CDC method 6306.03, which included HPLC with electrospray ionization-tandem mass spectrometry (Calafat, 2010). Process and instrument blanks were included for quality assurance. The limit of detection (LOD) was between 0.2 and 2.0 ng/mL for UW and 0.2–0.6 ng/mL for CDC.

Eleven individual phthalate metabolites (mono-isobutyl phthalate (MIBP), MEP, mono-*n*-butyl phthalate (MNBP), mono-benzyl phthalate (MBZP), mono-carboxy-isononyl phthalate (MCNP), mono-carboxy-isooctyl phthalate (MCOP), mono-(3-carboxypropyl) phthalate (MCPP), mono-(2-ethylhexyl) phthalate (MEHP), mono-(2-ethyl-5-hydroxyhexyl) phthalate (MEHHP), mono-(2-ethyl-5-oxohexyl) phthalate (MEOHP), mono-(2-ethyl-5-carboxypentyl) phthalate (MECPP)) and the molar sum of DEHP metabolites (Ferguson et al., 2014b) (ΣDEHP) were included. T1 MCOP and MCNP were only available for mothers of male infants, while T3 MCOP and MCNP were available for mothers of both male and female infants. All urinary phthalates were corrected for dilution using SG measurements with the following formula: $P_c = P [(SG_{\text{median}} - 1)/SG - 1]$ (P_c = SG-corrected concentration; P = measured urinary concentration; SG = specific gravity for the individual sample; SG_{median} = median SG over all samples) (Ferguson et al., 2014b). The metabolites were also natural log (ln)-transformed to approximate normal distributions. To calculate ΣDEHP , we divided each

metabolite by its molecular weight and summed these totals (Hauser et al., 2016). Correlations between SG-adjusted T1 and T3 phthalates were assessed through Spearman correlation coefficients.

We utilized two exposure metrics: 1) arithmetic mean of ln-transformed, SG-adjusted T1 and T3 urinary phthalate metabolite concentrations (“T1T3avg”), and 2) ln-transformed, SG-adjusted T1 urinary phthalate metabolite concentrations. The subject-specific T1T3avg, our primary exposure metric, was used to reduce exposure misclassification and obtain a more representative measure, given that phthalates are non-persistent chemicals that exhibit variability over time (Fisher et al., 2015). T1 concentrations were utilized because this exposure assessment preceded glucose tolerance testing.

2.3. Outcome assessment

GDM screening occurred during weeks 24–28 of pregnancy. The most common GDM screening approach, and the one utilized by all TIDES clinics, is a two-step test, comprised of a 1-h 50-g glucose load test (GLT) followed by a 3-h 100-g oral glucose tolerance test (OGTT) for those who screen positive in the initial GLT (American Diabetes, 2014; Vandersten et al., 2012). GDM is diagnosed in women with two or more abnormal values in the OGTT. Because of varying diagnostic thresholds (American College of Obstetricians and Gynecologists (ACOG), 2018; Carpenter and Coustan, 1982; National Diabetes Data, 1979), we standardized across the TIDES clinics with respect to GLT and OGTT test results. We classified a GLT result of ≥ 135 mg/dL as GLT exceedance/failure, since this was the midpoint of the threshold used across TIDES clinics. We then utilized results from the OGTT to classify women using the Carpenter-Coustan (CC) thresholds for exceedance (fasting: 95 mg/dL; 1 h: 180 mg/dL; 2 h: 155 mg/dL; and 3 h: 140 mg/dL) (Carpenter and Coustan, 1982). IGT was defined as a failed GLT but less than two exceedances on the OGTT. Therefore, by definition, GDM and IGT are mutually exclusive. Blood glucose concentrations from the GLT were utilized in our continuous outcome analysis. Two GLT values ($x = 1$ & $x = 38$ mg/dL) deemed implausible by study clinicians were dropped.

2.4. Statistical analysis

Based on published literature and *a priori* model conceptualization, we considered the following covariates and precision variables in the analyses: maternal age (Hatch et al., 2008; Lao et al., 2006), maternal pre-pregnancy body mass index (BMI) (Torloni et al., 2009), gestational weight gain (GWG) (Hedderson et al., 2010), study center, race/ethnicity (Berkowitz et al., 1992; Caughey et al., 2010; Ferrara, 2007; Savitz et al., 2008; Thorpe et al., 2005), maternal education (Bouthoorn et al., 2015), smoking (Wendland et al., 2008), alcohol use (Bouthoorn et al., 2015), infant sex, parity, and gestational age at glucose testing (Di Cianni et al., 2003). Our final model, based on statistical significance of variables in stepwise model building, adjusted for maternal age, maternal pre-pregnancy BMI, study center, race/ethnicity, parity, and gestational age at glucose testing. Ultimately, we included BMI instead of GWG, because adjustment for GWG may have led to bias because of its possible role as a mediator.

We first conducted univariate analyses of covariates and then assessed the relation between covariates and outcomes. For the primary inferential analyses, we used multivariable regression models to estimate associations between T1T3avg urinary MEP concentrations and outcomes of interest (logistic regression: odds ratio (OR) of GDM or IGT; linear regression: difference in blood glucose concentrations from the GLT). In secondary analyses, we estimated associations between: 1) T1T3avg urinary phthalate concentrations (for all other individual phthalates separately and Σ EDEHP metabolites) and the outcomes; and 2) T1 urinary phthalate concentrations (for all individual phthalates separately and Σ EDEHP metabolites) and the outcomes. To enhance comparability and interpretation, we present results in terms of an

interquartile range (IQR) difference in phthalate metabolite concentrations.

Since most studies suggest that women with polycystic ovary syndrome (PCOS) are at increased risk for GDM (Ben-Haroush et al., 2003; Toulis et al., 2009), we conducted sensitivity analyses excluding individuals with PCOS ($n = 45$). Additionally, because of the strong associations of race/ethnicity with phthalate exposure (Huang et al., 2014; Mitro et al., 2018) and glucose intolerance (Berkowitz et al., 1992; Caughey et al., 2010) as well as the differing associations between BMI and glucose tolerance by race (Hsu et al., 2015), we used interaction and stratification by group to assess potential racial/ethnic-specific effects. We also created phthalate exposure quartiles to evaluate possible non-linear associations.

To address potential concerns with reverse causality and/or changes in metabolism due to disease status, we conducted a sensitivity analysis of our primary aim after dropping individuals whose T3 urine samples were obtained after their prenatal visit with GLT screening ($n = 47$). To evaluate the potential influence of between-lab differences in LODs, we included laboratory as a covariate in the models.

All analyses were performed using STATA (version 14.1, StataCorp, College Station, TX, USA) with complete case analysis.

3. Results

Table 1 describes our study population for this analysis ($n = 705$). Our cohort was predominantly non-Hispanic white (66.4%) and well educated (74.2% had college/post-graduate education). Average maternal age was 31 years (standard deviation (SD) = 5.6 years), and average first trimester BMI was 26.1 kg/m² (SD = 6.2 kg/m²).

We observed 60 cases of GDM and 90 cases of IGT in the cohort, for overall frequencies of 8.5% and 12.8% respectively. As noted above, these outcomes are mutually exclusive. The prevalence of these conditions varied by race/ethnicity ($p = 0.04$) (Table A1). GDM was observed in 6.6% of the non-Hispanic white population but in 16.4% of Hispanics, 15.6% of Asians, and 11.1% of Blacks. IGT was observed in 15.6% of the Asian population, compared to 13.2% in the non-Hispanic white population. The mean (SD) glucose concentration in the GLT test was 113.6 (27.7) mg/dL across the cohort; Asians had the highest mean glucose concentrations among race/ethnic subgroups (121.9 (24.8) mg/dL).

Summary statistics on phthalate metabolites and Spearman correlation coefficients are found in Table 2. Within-woman, between-trimester correlations were low, ranging from 0.11 for Σ EDEHP to 0.46 for mBzP.

3.1. Primary & secondary analyses

Regression results are presented Figs. 1–2 and Table 3, and IQRs are presented in Table A2. Because regression results for individual DEHP metabolites were similar, results are presented for Σ EDEHP only. Our primary analysis indicated that T1T3avg MEP was associated with increased odds of GDM (OR (95% CI) per IQR increase: 1.61 (1.10, 2.36)). In secondary analyses, other T1T3avg phthalate metabolites were generally found to have slight positive associations; however, the confidence intervals were wide and overlapped the null, suggesting no overall effect. Most T1 metabolites were estimated to have negative associations; yet with the exception of MCPP ([OR (95% CI) per IQR increase]: (0.64 (0.43, 0.96)), these confidence intervals were also consistent with no effect. Analyses of both exposure metrics of phthalate metabolites with IGT generally suggested slight positive associations; most of these confidence intervals overlapped the null, indicating no effect, with the exception of T1T3avg MNBP ([OR (95% CI) per IQR increase]: 1.32 (1.00, 1.75)). Finally, our analyses suggested positive associations between phthalate metabolites and blood glucose difference for both exposure metrics. However, only the confidence intervals for MCOP excluded the null ((blood glucose difference (95%CI) per IQR

Table 1
Demographic characteristics of mothers included in analyses.^a

Characteristic	Total (n = 705) n (%)	GDM (n = 60) n (%)	IGT (n = 90) n (%)
Study center			
University of California, San Francisco (UCSF)	165 (23.4)	20 (33.3)	21 (23.3)
University of Minnesota (UMN)	192 (27.2)	8 (13.3)	31 (34.4)
University of Rochester Medical Center (URMC)	201 (28.5)	15 (25)	25 (27.8)
University of Washington (UW)	131 (18.6)	17 (28.3)	11 (12.2)
Maternal age (years)			
≤ 20	21 (2.9)	1 (1.7)	2 (2.2)
21–30	262 (37.2)	20 (33.3)	31 (34.4)
31–40	393 (55.7)	31 (51.7)	54 (60.0)
> 40	29 (4.1)	8 (13.3)	3 (3.3)
Pre-pregnancy body mass index (BMI) (kg/m²)			
≤ 24.9	379 (53.8)	23 (38.3)	42 (46.7)
25–29.9	155 (22.0)	11 (18.3)	27 (30.0)
≥ 30	159 (22.6)	24 (40.0)	21 (23.3)
Race/ethnicity category			
Non-Hispanic White	468 (66.4)	31 (51.7)	62 (68.9)
Non-Hispanic Black	81 (11.5)	9 (15.0)	8 (8.9)
Non-Hispanic Asian	38 (5.4)	6 (10.0)	6 (6.7)
Hispanic	55 (7.8)	9 (15.0)	5 (5.6)
Other/mixed	49 (6.9)	5 (8.3)	6 (6.7)
Highest education attended			
High school or less	97 (13.8)	8 (13.3)	11 (12.2)
Some college	85 (12.1)	7 (11.7)	13 (14.4)
College/post-graduate	523 (74.2)	45 (75.0)	66 (73.3)
Any smoking during pregnancy			
Yes	47 (6.7)	4 (6.7)	7 (7.8)
No	591 (83.4)	50 (83.3)	75 (83.3)
Any alcohol during pregnancy			
Yes	91 (12.9)	7 (11.7)	10 (11.1)
No	546 (77.4)	48 (80.0)	71 (78.9)
Infant sex			
Boy	323 (45.8)	33 (55.0)	44 (48.9)
Girl	345 (48.9)	27 (45.0)	41 (45.6)
Previous live birth			
Yes	296 (42.0)	22 (36.7)	44 (48.9)
No	367 (52.0)	35 (58.3)	43 (47.8)

^a Summaries provided for entire cohort (total) and also stratified by diagnosis (gestational diabetes (GDM) or impaired glucose tolerance (IGT)).

Table 2
Descriptive data for phthalate metabolites.

Phthalate metabolite	T1 ^a			T3 ^b			T1 T3 Spearman correlation ^g
	N	% > LOD ^c	GM ^d (GSD) ^{e,f}	N	% > LOD	GM (GSD)	
Mono-isobutyl phthalate (MIBP)	668	99	5.2 (2.4)	679	95	7.2 (2.6)	0.40
Monoethyl phthalate (MEP)	668	100	37.6 (3.8)	679	98	42.1 (4.5)	0.40
Mono- <i>n</i> -butyl phthalate (MNBP)	668	95	8.3 (2.4)	679	98	9.7 (2.7)	0.27
Mono-benzyl phthalate (MBZP)	668	95	4.3 (2.9)	679	95	4.8 (3.2)	0.46
Mono-carboxy-isononyl phthalate (MCNP)	406	96	2.7 (2.8)	679	98	2.8 (2.7)	0.15
Mono-carboxy-isooctyl phthalate (MCOP)	406	100	19.3 (3.5)	679	100	16.0 (3.3)	0.27
Mono-(3-carboxypropyl) phthalate (MCPP)	668	94	2.5 (3.6)	679	87	2.4 (3.7)	0.20
Mono-(2-ethylhexyl) phthalate (MEHP)	668	70	2.5 (2.5)	679	76	2.1 (2.4)	0.14
Mono-(2-ethyl-5-hydroxyhexyl) phthalate (MEHHP)	668	100	7.9 (2.6)	679	99	6.7 (2.5)	0.12
Mono-(2-ethyl-5-oxohexyl) phthalate (MEOHP)	668	99	5.5 (2.5)	679	100	5.3 (2.5)	0.13
Mono-(2-ethyl-5-carboxypentyl) phthalate (MECPP)	668	100	10.6 (2.4)	679	100	12.2 (2.3)	0.20
ΣDi-2-ethylhexyl phthalate (DEHP)	668	N/A	93.4 (2.3)	679	N/A	47.7 (2.4)	0.11

^a T1 = First trimester.

^b T3 = Third trimester.

^c LOD = Limit of detection.

^d GM = Geometric mean.

^e GSD = Geometric standard deviation.

^f Units are µg/L for all individual phthalates; nmol/mL for ΣDEHP.

^g Within-woman, between-trimester correlations on SG-adjusted phthalates.

increase) T1: 1.91 (0.25, 3.55), T1T3avg: 1.50 (0.02, 2.98)).

3.2. Sensitivity analyses

Sensitivity analyses excluding individuals with PCOS did not alter results. Race/ethnicity-stratified analyses adjusting for maternal age, maternal BMI, and parity suggested associations between several phthalates on blood glucose among Asians only (Table A3). Quartile analyses did not indicate any non-linear associations (results not shown). Sensitivity analyses excluding women whose T3 urine samples occurred after GLT (n = 47) and adjusting for laboratory did not change our estimates (results not shown).

4. Discussion

Our primary finding that T1T3avg MEP is significantly associated with increased odds of GDM (OR (95%CI): 1.61 (1.10, 2.36)) supports our *a priori* primary analytical hypothesis and previous studies suggesting associations with GDM risk factors and blood glucose (James-Todd et al., 2018; James-Todd et al., 2016). In secondary analyses, most other phthalates were not found to be associated with study outcomes; however, we did detect a positive association between T1T3avg MNBP and IGT, and between both T1T3avg and T1 MCOP and blood glucose. By contrast, T1 MCPP was found to be inversely associated with GDM.

Previously, five studies had evaluated the association between phthalate exposure and outcomes related to gestational glucose intolerance. It is challenging to draw overall conclusions from this body of work, given their disparate results. Yet, of relevance, MEP has been positively associated with both IGT (James-Todd et al., 2016) and blood glucose (James-Todd et al., 2018), though two other studies observed no association (Fisher et al., 2018; Robledo et al., 2015). Other phthalate metabolites have been estimated to have both negative and positive associations with gestational glucose tolerance outcomes, though many of these estimates had wide confidence intervals overlapping the null (Fisher et al., 2018; James-Todd et al., 2018; James-Todd et al., 2016; Robledo et al., 2015; Shapiro et al., 2015). In the only previous study to assess GDM in relation to phthalates (Shapiro et al., 2015), wide confidence intervals for all metabolites precluded any meaningful conclusions; though some metabolites were associated with increased risk while others were associated with decreased risk (Shapiro et al., 2015). In that study, Shapiro et al. evaluated phthalates using only T1 urine samples, which may not capture the relevant




Fig. 1. Phthalates in association with GDM. Adjusted odds ratio (OR) and 95% confidence interval (95% CI) for the association between one interquartile range (IQR) increase in urinary phthalate metabolite and gestational diabetes mellitus (GDM).¹ A) T1T3avg phthalate metabolite; B) T1 phthalate metabolite.
¹Model adjusted for maternal age, maternal BMI, study center, race/ethnicity, parity, and gestational age at glucose testing.

exposure period given their short half-life (Fromme et al., 2007). Furthermore, they utilized different criteria for OGTT results, based on Canadian guidelines (Berger et al., 2002) that are less conservative than the classifications we used. These less stringent diagnostic criteria may partially account for their null findings.

The overall prevalence of GDM in our population was 8.5%, consistent with national estimates of 8–9% (DeSisto et al., 2014). The prevalence of GDM was highest in Asians and Hispanic subgroups (15.8% and 16.4%, respectively) (Table A1); national estimates and previous studies have also documented high burdens of metabolic conditions in these subgroups (Ferrara, 2007; Thorpe et al., 2005). Concentrations of phthalate metabolites detected in our cohort of pregnant women (Table 2) were similar to those found in nationally representative data from the general population in the 2011–2012 National Health and Nutrition Examination Survey (NHANES) (Centers for Disease Control and Prevention, 2018) and for the full TIDES cohort (Swan et al., 2015). We found that within woman, between trimester correlations of SG-adjusted phthalate metabolite concentrations were moderately low, ranging from 0.11 for ΣDEHP metabolites to 0.46 for MBZP (Table 2). Our findings are consistent with previous studies of pregnant populations that have documented low to moderate correlations between phthalates at different timepoints (Adibi et al., 2008;

Table 3

Adjusted mean difference in glucose concentration (mg/dL) and 95% CI measured during glucose load test associated with one IQR increase in urinary phthalate metabolites.^a

Phthalate	T1 estimates	T1T3avg estimates
MIBP	−0.03 (−1.84, 1.79)	0.19 (−1.26, 1.63)
MEP	0.11 (−1.05, 1.28)	0.60 (−0.25, 1.44)
MNBP	0.60 (−1.17, 2.37)	0.88 (−0.62, 2.36)
MBZP	−0.19 (−1.74, 1.35)	0.01 (−1.20, 1.21)
MCNP	−0.52 (−2.47, 1.44)	−0.70 (−2.30, 0.91)
MCOP	1.91 (0.25, 3.55)	1.50 (0.02, 2.98)
MCPP	−0.13 (−1.31, 1.05)	0.09 (−0.85, 1.01)
ΣDEHP	0.29 (−1.51, 2.08)	0.56 (−0.91, 2.02)

^a Model adjusted for maternal age, maternal BMI, study center, race/ethnicity, parity, and gestational age at glucose testing. IQR = interquartile range.

Ferguson et al., 2014a; Valvi et al., 2015), which helped to inform our decision to use T1T3avg phthalates as the primary exposure variable.

Phthalates may alter glucose metabolism through several mechanisms. They can selectively modulate PPARs, altering lipid processing and glucose homeostasis (Desvergne et al., 2009; Grun and Blumberg, 2007; Liu and Sun, 2016; Sarath Josh et al., 2014; Tordjman et al.,




Fig. 2. Phthalates in association with IGT. Adjusted odds ratio (OR) and 95% confidence interval (95% CI) for the association between one interquartile range (IQR) increase in phthalate and IGT.¹ A) T1T3avg phthalate metabolite; B) T1 phthalate metabolite.
¹Model adjusted for maternal age, maternal BMI, study center, race/ethnicity, parity, and gestational age at glucose testing.

2002). Phthalates are also known endocrine disruptors, linked to changes in sex steroid hormones and related outcomes (Diamanti-Kandarakis et al., 2009), and several phthalates have been found to have estrogenic activity specifically (Harris et al., 1997; Jobling et al., 1995; Sathyanarayana et al., 2017). Substantial evidence indicates that alterations in estrogens are linked to insulin resistance, changes in adipocytes, and related metabolic disruptions in females (Chen et al., 2009; Ding et al., 2007; Liu and Sun, 2016; Livingstone and Collison, 2002; Louet et al., 2004; Pallottini et al., 2008). In the short term, phthalate-driven elevations in estrogen could lead to increased insulin signaling through an estrogen receptor alpha (ERalpha)-mediated pathway. However, over time, prolonged activation could result in excess insulin release, beta cell exhaustion, and peripheral insulin resistance (Aston-Mourney et al., 2008; Nadal et al., 2009). Some but not all experimental studies support a link between phthalates and abnormal glucose metabolism, including changes in insulin signaling molecules, glucose transporters, glucose uptake, and blood glucose concentrations after exposure (Rajesh et al., 2013; Rengarajan et al., 2007; Srinivasan et al., 2011; Viswanathan et al., 2017). MEP, the *a priori* focus of our study, may act by estrogenic and/or PPAR-related pathways (Guven et al., 2016).

Certain racial/ethnic groups, particularly Asians, have higher risk of GDM and other metabolic disorders (Ferrara, 2007; Thorpe et al., 2005). Sensitivity analyses to evaluate our study question using race-stratification suggested elevated risk among Asians from numerous phthalate metabolites (Table A3). This exploratory finding is interesting given that, while Asians are at highest risk for GDM and other metabolic diseases, they have low rates of obesity, one of the strongest risk factors (Hedderston et al., 2012). Genetic factors may play a role in the observed susceptibility among Asians. The PPARgamma2 polymorphism Pro12Ala is associated with decreased risk of diabetes (Stumvoll and Haring, 2002). Due to reduced binding of this variant to PPARgamma-responsive DNA elements, there is altered production and release of adipose factors, including reductions in free fatty acids, TNF-alpha, and resistin – all of which reduce insulin sensitivity – and increases in adiponectin – which improves insulin sensitivity (Stumvoll and Haring, 2002). Given that PPARgamma is one possible mode of action of phthalates on insulin resistance, individuals with this variant would be less susceptible to phthalate-mediated insulin resistance. The prevalence of this polymorphism varies by race, with the highest frequencies among Caucasians (~12%) and the lowest among certain Asian groups [e.g. Japanese (~4%), Chinese (%1)] and African Americans (~3%)] (Mori et al., 2001; Stumvoll and Haring, 2002; Vigouroux et al., 1998). The low frequency of this protective variant among Asians may confer greater vulnerability to the effects of exposure. Ethnic and cultural differences in diet, particularly with respect to high glycemic foods, also likely play a role (Hiza et al., 2013; Zhang and Ning, 2011).

Our research has several limitations. Phthalate metabolites were only measured in two samples per woman, but phthalate concentrations during pregnancy can change considerably from day-to-day (Fisher et al., 2015). Furthermore, T1 MCOP and MCNP were only available on a subset of the population, which reduced our sample size for these analyses. We were unable to adjust for several confounders, including prior GDM in pregnancy, prior T2DM, or family history of T2DM (Kim et al., 2007); diet (Serrano et al., 2014; Zhang and Ning, 2011); and/or other exogenous compounds with similar exposure sources also linked to diabetes and metabolic dysfunction, such as bisphenol-A (Song et al., 2015). Additionally, we were underpowered to thoroughly evaluate racial/ethnic subpopulations and did not have detailed information on the different sub-groups within this category, suggesting that a very cautious interpretation of our intriguing findings from sensitivity analyses is warranted. Finally given the uncertainty regarding the critical windows of exposure for GDM, we cannot be certain that exposure

assessment preceded initiation of the disease process. Future research to elucidate disease progression can inform the design of epidemiological studies that can more accurately assess exposure during critical windows.

Despite these limitations, our study had important strengths. The TIDES cohort is derived from four centers across the country, providing geographic diversity not present in some prior studies. Furthermore, our study is unique in utilizing phthalate measures from two timepoints during pregnancy. The low within-woman correlation between T1 and T3 phthalates underscores the importance of utilizing multiple exposure measurements. Finally, we also had access to continuous measures of glucose intolerance. These data allowed us to investigate not only the clinical outcome of GDM but also subclinical measures of glucose intolerance linked to adverse pregnancy outcomes (The HAPO Study Cooperative Research Group, 2008) but not as thoroughly investigated.

5. Conclusion

Overall, this study adds to growing literature on the association between phthalates and gestational glucose intolerance and in particular provides additional data to support the link between MEP and GDM. There are several mechanisms by which phthalates may affect metabolic function and, given the significant maternal and fetal consequences of hyperglycemia during pregnancy, research should continue to address this subject – especially in susceptible populations.

Declarations of interest

None.

Funding

RMS is supported by the Seattle Chapter of the ARCS Foundation and NIEHS T32ES015459. TIDES is funded by NIEHS R01ES0125169-01. This research was supported in part by the Intramural Research Program of the National Institute of Environmental Health Sciences, National Institutes of Health (ZIA103313), and NIH-NIEHS P30 ES005022. The funding sources had no role in the design, collection, analysis, or interpretation of the data, nor the writing of the publication.

Disclaimer

The views expressed in this publication do not necessarily reflect the views of the funding agencies or the federal government.

Acknowledgements

We thank Dr. Sarah Lowry (Seattle Children's Research Institute) for her statistical programming support during the analysis and Dr. Antonia Calafat (Centers for Disease Control and Prevention) for the coordination and processing of urine sample analyses.

We would also like to thank the TIDES study team: Garry Alcedo (UW), Sabrina Bedell (UMN), Ashley Carter (UW), Sarah Caveglia (URMC), Alana Cordeiro (UCSF), Sarah Evans (Mt. Sinai School of Medicine), Andrea Hart (URMC), Savannah King (UCSF), Ellen Laschansky (UW), Stacey Moe (UMN), Ashley Santilli (UMN), and Simar Singh (UCSF). The TIDES study team was funded by NIEHS R01ES0125169-01.

Finally, we also acknowledge and thank the TIDES study participants who made this study possible.

Appendix A. Appendix

A1

Race-specific and overall frequencies of glucose intolerance outcomes in study population.^a

Race/Ethnicity	n	GDM (n (%))	IGT (n (%))	GLT (mean (SD)(mg/dL))
Non-Hispanic White	468	31 (6.6)	62 (13.2)	112.9 (27.1)
Non-Hispanic Black	81	9 (11.1)	8 (9.9)	108.3 (31.0)
Non-Hispanic Asian	38	6 (15.8)	6 (15.8)	121.9 (24.8)
Hispanic	55	9 (16.4)	5 (9.1)	114.6 (29.9)
Other/mixed	49	5 (10.2)	6 (12.2)	119.0 (25.7)
Missing	14	0 (0)	3 (21.4)	118.9 (25.0)
Total	705	60 (8.5)	90 (12.8)	113.6 (27.7)

^a GDM = Gestational diabetes; IGT = impaired glucose tolerance; GLT = glucose load test; SD = standard deviation.

A2

Interquartile range (IQR) for ln-transformed phthalate metabolites.

Phthalate	T1 IQR	T1T3avg IQR
MIBP	1.1	0.9
MEP	1.8	1.8
MNBP	1.1	0.9
MBZP	1.4	1.3
MCNP	1.3	1.2
MCOP	1.7	1.6
MCPP	1.6	1.5
MEHP	1.1	0.8
MEHHP	1.0	0.9
MEOHP	1.0	0.8
MECPP	1.0	0.8
ΣDEHP	0.9	0.9

A3

Race-stratified adjusted mean difference in glucose concentration (mg/dL) in the glucose load test (GLT) associated with one IQR increase in T1T3avg phthalate.^a

Phthalate	White ^b	Black ^c	Asian ^d	Hispanic ^e
MIBP	-0.78 (-2.49, 0.93)	0.56 (-3.77, 7.03)	10.73* (5.29, 14.59)	0.41 (-5.42, 6.33)
MEP	0.38 (-0.62, 1.38)	-0.14 (-2.70, 2.41)	4.80* (1.39, 8.21)	0.25 (-2.75, 3.26)
MNBP	0.14 (-1.29, 1.58)	0.46 (-3.81, 4.73)	4.60* (0.85, 8.36)	-0.10 (-5.10, 4.90)
MBZP	-0.23 (-2.74, 2.28)	-1.79 (-5.37, 1.78)	10.65 (-0.46, 21.78)	0.34 (-7.53, 8.22)
MCNP	-2.66 (-7.33, 1.99)	-4.41 (-24.54, 15.72)	1.49 (-11.34, 14.33)	-5.85 (-17.92, 6.21)
MCOP	1.36 (-0.53, 3.24)	3.96 (-0.80, 8.72)	0.98 (-5.41, 7.36)	-2.36 (-7.72, 3.00)
MCPP	-0.27 (-4.11, 3.56)	0.17 (-8.34, 8.67)	11.53 (-9.40, 32.43)	0.18 (-9.70, 10.05)
MEHP	-0.25 (-4.07, 3.56)	0.35 (-8.45, 9.16)	7.74 (-6.24, 21.71)	2.69 (-11.02, 16.42)
MEHHP	-0.30 (-1.65, 1.04)	1.07 (-2.29, 4.43)	4.24* (0.81, 7.67)	-1.48 (-6.95, 3.98)
MEOHP	-0.29 (-1.82, 1.25)	0.32 (-3.75, 4.39)	5.26* (0.79, 9.74)	-0.96 (-6.86, 4.95)
MECPP	-0.29 (-1.48, 0.90)	0.73 (-2.48, 3.94)	3.74* (0.81, 6.67)	-1.51 (-6.87, 3.86)
ΣDEHP	-0.004 (-0.69, 0.68)	0.14 (-2.03, 2.31)	2.59* (0.41, 4.76)	-0.41 (-2.77, 1.95)

^a Model adjusted for maternal age, maternal BMI, and parity. Star denotes statistical significance at the 0.05 alpha level. IQR = interquartile range.

^b n = 413; MCOP/MCNP n = 249.

^c n = 68; MCOP/MCNP n = 38.

^d n = 35; MCOP/MCNP n = 21.

^e n = 45; MCOP/MCNP n = 33.

References

Adibi, J.J., Whyatt, R.M., Williams, P.L., Calafat, A.M., Camann, D., Herrick, R., Nelson, H., Bhat, H.K., Perera, F.P., Silva, M.J., Hauser, R., 2008. Characterization of phthalate exposure among pregnant women assessed by repeat air and urine samples. *Environ. Health Perspect.* 116, 467–473.

Albrecht, S.S., Kuklina, E.V., Bansil, P., Jamieson, D.J., Whiteman, M.K., Kourtis, A.P., Posner, S.F., Callaghan, W.M., 2010. Diabetes trends among delivery hospitalizations in the United States, 1994–2004. *Diabetes Care* 33 (4), 768–773.

American College of Obstetricians and Gynecologists (ACOG), 2018. ACOG practice bulletin no. 190 summary: gestational diabetes mellitus. *Obstet. Gynecol.* 131, 406–408.

American Diabetes, A, 2014. Standards of medical care in diabetes—2014. *Diabetes Care* 37, S14–S80.

American Diabetes Association, 2012. Standards of medical care in diabetes—2013. *Diabetes Care* 36, S11.

Aston-Mourney, K., Proietto, J., Morahan, G., Andrikopoulos, S., 2008. Too much of a good thing: why it is bad to stimulate the beta cell to secrete insulin. *Diabetologia* 51, 540–545.

Bardenheier, B.H., Imperatore, G., Gilboa, S.M., Geiss, L.S., Saydah, S.H., Devlin, H.M., Kim, S.Y., Gregg, E.W., 2015. Trends in gestational diabetes among hospital deliveries in 19 U.S. states, 2000–2010. *Am. J. Prev. Med.* 49, 12–19.

Ben-Haroush, A., Yogeve, Y., Hod, M., 2003. Epidemiology of gestational diabetes mellitus and its association with Type 2 diabetes. *Diabet. Med.* 21, 103–113.

Berger, H., Crane, J., Farine, D., Armson, A., De, S.L.R., Keenan-Lindsay, L., Leduc, L., Reid, G., Van, J.A., 2002. Screening for gestational diabetes mellitus. *Journal of obstetrics and gynaecology Canada. J. Obstet. Gynaecol. Can.* 24, 894–912.

Berkowitz, G.S., Lapinski, R.H., Wein, R., Lee, D., 1992. Race/ethnicity and other risk factors for gestational diabetes. *Am. J. Epidemiol.* 135, 965–973.

- Bouthoorn, S.H., Silva, L.M., Murray, S.E., Steegers, E.A., Jaddoe, V.W., Moll, H., Hofman, A., Mackenbach, J.P., Raat, H., 2015. Low-educated women have an increased risk of gestational diabetes mellitus: the Generation R Study. *Acta Diabetol.* 52, 445–452.
- Calafat, A.M., 2010. Phthalate Metabolites Method 6306.03. Centers for Disease Control and Prevention, Atlanta, GA.
- Carpenter, M.W., Coustan, D.R., 1982. Criteria for screening tests for gestational diabetes. *Am. J. Obstet. Gynecol.* 144, 768–773.
- Catalano, P.M., Tyzibir, E.D., Sims, E.A.H., 1990. Incidence and significance of islet cell antibodies in women with previous gestational diabetes. *Diabetes Care* 13, 478–482.
- Catalano, P.M., Nizielski, S.E., Shao, J., Preston, L., Qiao, L., Friedman, J.E., 2002. Downregulated IRS-1 and PPARgamma in obese women with gestational diabetes: relationship to FFA during pregnancy. *Am. J. Physiol. Endocrinol. Metab.* 282, E522–E533.
- Caughey, A.B., Cheng, Y.W., Stotland, N.E., Washington, A.E., Escobar, G.J., 2010. Maternal and paternal race/ethnicity are both associated with gestational diabetes. *Am. J. Obstet. Gynecol.* 202 (616.e611–615).
- Centers for Disease Control and Prevention, 2018. Fourth Report on Human Exposure to Environmental Chemicals, Updated Tables. U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, Atlanta, GA.
- Chen, X., Scholl, T.O., 2005. Oxidative stress: changes in pregnancy and with gestational diabetes mellitus. *Curr. Diab. Rep.* 5, 282–288.
- Chen, J.Q., Brown, T.R., Russo, J., 2009. Regulation of energy metabolism pathways by estrogens and estrogenic chemicals and potential implications in obesity associated with increased exposure to endocrine disruptors. *Biochim. Biophys. Acta* 1793, 1128–1143.
- Chu, S.Y., Callaghan, W.M., Kim, S.Y., Schmid, C.H., Lau, J., England, L.J., Dietz, P.M., 2007. Maternal obesity and risk of gestational diabetes mellitus. *Diabetes Care* 30, 2070.
- Coughlan, M.T., Vervaart, P.P., Permezel, M., Georgiou, H.M., Rice, G.E., 2004. Altered placental oxidative stress status in gestational diabetes mellitus. *Placenta* 25, 78–84.
- Coustan, D.R., Lowe, L.P., Metzger, B.E., Dyer, A.R., 2010. The Hyperglycemia and Adverse Pregnancy Outcome (HAPO) study: paving the way for new diagnostic criteria for gestational diabetes mellitus. *Am. J. Obstet. Gynecol.* 202 (654.e651–656).
- DeSisto, C.L., Kim, S.Y., Sharma, A.J., 2014. Prevalence estimates of gestational diabetes mellitus in the United States, Pregnancy Risk Assessment Monitoring System (PRAMS), 2007–2010. *Prev. Chronic Dis.* 11, E104.
- Desvergne, B., Feige, J.N., Casals-Casas, C., 2009. PPAR-mediated activity of phthalates: a link to the obesity epidemic? *Mol. Cell. Endocrinol.* 304, 43–48.
- Di Cianni, G., Miccoli, R., Volpe, L., Lencioni, C., Del Prato, S., 2003. Intermediate metabolism in normal pregnancy and in gestational diabetes. *Diabetes Metab. Res. Rev.* 19, 259–270.
- Diamanti-Kandarakis, E., Bourguignon, J.-P., Giudice, L.C., Hauser, R., Prins, G.S., Soto, A.M., Zoeller, R.T., Gore, A.C., 2009. Endocrine-disrupting chemicals: an endocrine society scientific statement. *Endocr. Rev.* 30, 293–342.
- Ding, E.L., Song, Y., Manson, J.E., Rifai, N., Buring, J.E., Liu, S., 2007. Plasma sex steroid hormones and risk of developing type 2 diabetes in women: a prospective study. *Diabetologia* 50, 2076–2084.
- Ehrlich, S., Lambers, D., Baccarelli, A., Khoury, J., Macaluso, M., Ho, S.M., 2016. Endocrine disruptors: a potential risk factor for gestational diabetes mellitus. *Am. J. Perinatol.* 33, 1313–1318.
- Ferguson, K.K., McElrath, T.F., Ko, Y.A., Mukherjee, B., Meeker, J.D., 2014a. Variability in urinary phthalate metabolite levels across pregnancy and sensitive windows of exposure for the risk of preterm birth. *Environ. Int.* 70, 118–124.
- Ferguson, K.K., McElrath, T.F., Meeker, J.D., 2014b. Environmental phthalate exposure and preterm birth. *JAMA Pediatr.* 168, 61–67.
- Ferrara, A., 2007. Increasing prevalence of gestational diabetes mellitus. *Diabetes Care* 30, S141.
- Fisher, M., Arbuckle, T.E., Mallick, R., LeBlanc, A., Hauser, R., Feeley, M., Koniecki, D., Ramsay, T., Provencher, G., Bérubé, R., 2015. Bisphenol A and phthalate metabolite urinary concentrations: daily and across pregnancy variability. *J. Expo. Sci. Environ. Epidemiol.* 25, 231.
- Fisher, B.G., Frederiksen, H., Andersson, A.-M., Juul, A., Thankamony, A., Ong, K.K., Dunger, D.B., Hughes, I.A., Acerini, C.L., 2018. Serum phthalate and triclosan levels have opposing associations with risk factors for gestational diabetes mellitus. *Front. Endocrinol.* 9, 99.
- Fromme, H., Bolte, G., Koch, H.M., Angerer, J., Boehmer, S., Drexler, H., Mayer, R., Liebl, B., 2007. Occurrence and daily variation of phthalate metabolites in the urine of an adult population. *Int. J. Hyg. Environ. Health* 210, 21–33.
- Grun, F., Blumberg, B., 2007. Perturbed nuclear receptor signaling by environmental obsolegens as emerging factors in the obesity crisis. *Rev. Endocr. Metab. Disord.* 8, 161–171.
- Güven, C., Dal, F., Aydoğan Ahabab, M., Taskin, E., Ahabab, S., Adin Cinar, S., Sirma Ekmekci, S., Gulec, C., Abaci, N., Akcakaya, H., 2016. Low dose monoethyl phthalate (MEP) exposure triggers proliferation by activating PDX-1 at 1.1B4 human pancreatic beta cells. *Food Chem. Toxicol.* 93, 41–50.
- Harris, C.A., Henttu, P., Parker, M.G., Sumpter, J.P., 1997. The estrogenic activity of phthalate esters in vitro. *Environ. Health Perspect.* 105, 802.
- Hatch, E.E., Nelson, J.W., Qureshi, M.M., Weinberg, J., Moore, L.L., Singer, M., Webster, T.F., 2008. Association of urinary phthalate metabolite concentrations with body mass index and waist circumference: a cross-sectional study of NHANES data, 1999–2002. *Environ. Health* 7, 27.
- Hauser, R., Gaskins, A.J., Souter, I., Smith, K.W., Dodge, L.E., Ehrlich, S., Meeker, J.D., Calafat, A.M., Williams, P.L., 2016. Urinary phthalate metabolite concentrations and reproductive outcomes among women undergoing in vitro fertilization: results from the EARTH Study. *Environ. Health Perspect.* 124, 831–839.
- Hedderson, M.M., Gunderson, E.P., Ferrara, A., 2010. Gestational weight gain and risk of gestational diabetes mellitus. *Obstet. Gynecol.* 115, 597–604.
- Hedderson, M., Ehrlich, S., Sridhar, S., Darbinian, J., Moore, S., Ferrara, A., 2012. Racial/ethnic disparities in the prevalence of gestational diabetes mellitus by BMI. *Diabetes Care* 35, 1492–1498.
- Hiza, H.A.B., Casavale, K.O., Guenther, P.M., Davis, C.A., 2013. Diet quality of Americans differs by age, sex, race/ethnicity, income, and education level. *J. Acad. Nutr. Diet.* 113, 297–306.
- Holmes, H.J., Lo, J.Y., McIntire, D.D., Casey, B.M., 2010. Prediction of diabetes recurrence in women with class A1 (diet-treated) gestational diabetes. *Am. J. Perinatol.* 27, 047–052.
- Hsu, W.C., Araneta, M.R.G., Kanaya, A.M., Chiang, J.L., Fujimoto, W., 2015. BMI cut points to identify at-risk Asian Americans for type 2 diabetes screening. *Diabetes Care* 38, 150–158.
- Huang, T., Saxena, A.R., Isganaitis, E., James-Todd, T., 2014. Gender and racial/ethnic differences in the associations of urinary phthalate metabolites with markers of diabetes risk: National Health and Nutrition Examination Survey 2001–2008. *Environ. Health* 13, 6.
- James-Todd, T., Stahlhut, R., Meeker, J.D., Powell, S.G., Hauser, R., Huang, T., Rich-Edwards, J., 2012. Urinary phthalate metabolite concentrations and diabetes among women in the National Health and Nutrition Examination Survey (NHANES) 2001–2008. *Environ. Health Perspect.* 120, 1307–1313.
- James-Todd, T.M., Meeker, J.D., Huang, T., Hauser, R., Ferguson, K.K., Rich-Edwards, J.W., McElrath, T.F., Seely, E.W., 2016. Pregnancy urinary phthalate metabolite concentrations and gestational diabetes risk factors. *Environ. Int.* 96, 118–126.
- James-Todd, T.M., Chiu, Y.-H., Messerlian, C., Mínguez-Alarcón, L., Ford, J.B., Keller, M., Petrozza, J., Williams, P.L., Ye, X., Calafat, A.M., Hauser, R., 2018. Trimester-specific phthalate concentrations and glucose levels among women from a fertility clinic. *Environ. Health* 17, 55.
- Jobling, S., Reynolds, T., White, R., Parker, M.G., Sumpter, J.P., 1995. A variety of environmentally persistent chemicals, including some phthalate plasticizers, are weakly estrogenic. *Environ. Health Perspect.* 103, 582.
- Kim, C., Berger, D.K., Chamany, S., 2007. Recurrence of gestational diabetes mellitus. *Diabetes Care* 30, 1314.
- Lao, T.T., Ho, L.-F., Chan, B.C.P., Leung, W.-C., 2006. Maternal age and prevalence of gestational diabetes mellitus. *Diabetes Care* 29, 948.
- Lappas, M., Hiden, U., Desoye, G., Froehlich, J., Hauguel-de Mouzon, S., Jaberbaum, A., 2011. The role of oxidative stress in the pathophysiology of gestational diabetes mellitus. *Antioxid. Redox Signal.* 15, 3061–3100.
- Liu, S., Sun, Q., 2016. Sex differences, endogenous sex-hormone hormones, sex-hormone binding globulin, and exogenous disruptors in diabetes and related metabolic outcomes. *J. Diabetes* 10 (6), 428–441.
- Livingstone, C., Collison, M., 2002. Sex steroids and insulin resistance. *Clin. Sci. (Lond.)* 102, 151–166.
- Louet, J.-F., LeMay, C., Mauvais-Jarvis, F., 2004. Antidiabetic actions of estrogen: insight from human and genetic mouse models. *Curr. Atheroscler. Rep.* 6, 180–185.
- Mitro, S.D., Chu, M.T., Dodson, R.E., Adamkiewicz, G., Chie, L., Brown, F.M., James-Todd, T.M., 2018. Phthalate metabolite exposures among immigrants living in the United States: findings from NHANES, 1999–2014. *J. Expo. Sci. Environ. Epidemiol.* 1.
- Mori, H., Ikegami, H., Kawaguchi, Y., Seino, S., Yokoi, N., Takeda, J., Inoue, I., Seino, Y., Yasuda, K., Hanafusa, T., 2001. The Pro12 → Ala substitution in PPAR-γ is associated with resistance to development of diabetes in the general population: possible involvement in impairment of insulin secretion in individuals with type 2 diabetes. *Diabetes* 50, 891–894.
- Morisset, A.S., Tchernof, A., Dube, M.C., Veillette, J., Weisnagel, S.J., Robitaille, J., 2011. Weight gain measures in women with gestational diabetes mellitus. *J. Women's Health (Larchmt)* 20, 375–380.
- Nadal, A., Alonso-Magdalena, P., Soriano, S., Quesada, I., Ropero, A.B., 2009. The pancreatic beta-cell as a target of estrogens and xenoestrogens: implications for blood glucose homeostasis and diabetes. *Mol. Cell. Endocrinol.* 304, 63–68.
- National Diabetes Data, G., 1979. Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance. *Diabetes* 28, 1039–1057.
- National Research Council, 2008. Phthalates and Cumulative Risk Assessment The Task Ahead. The National Academies Press, Washington, DC.
- Pallottini, V., Bulzomi, P., Galluzzo, P., Martini, C., Marino, M., 2008. Estrogen regulation of adipose tissue functions: involvement of estrogen receptor isoforms. *Infect. Disord. Drug Targets* 8, 52–60.
- Rajesh, P., Sathish, S., Srinivasan, C., Selvaraj, J., Balasubramanian, K., 2013. Phthalate is associated with insulin resistance in adipose tissue of male rat: role of antioxidant vitamins. *J. Cell. Biochem.* 114, 558–569.
- Reece, E.A., 2010. The fetal and maternal consequences of gestational diabetes mellitus. *J. Matern. Fetal Neonatal Med.* 23, 199–203.
- Rengarajan, S., Parthasarathy, C., Anitha, M., Balasubramanian, K., 2007. Diethylhexyl phthalate impairs insulin binding and glucose oxidation in Chang liver cells. *Toxicol. in Vitro* 21, 99–102.
- Robledo, C.A., Peck, J.D., Calafat, A.M., Carabin, H., Cowan, L., Goodman, J.R., 2015. Urinary phthalate metabolite concentrations and blood glucose levels during pregnancy. *Int. J. Hyg. Environ. Health* 218, 324–330.
- Sarath Josh, M.K., Pradeep, S., Vijayalekshmi Amma, K.S., Balachandran, S., Abdul Jaleel, U.C., Doble, M., Spener, F., Benjamin, S., 2014. Phthalates efficiently bind to human peroxisome proliferator activated receptor and retinoid X receptor alpha, beta, gamma subtypes: an in silico approach. *J. Appl. Toxicol.* 34, 754–765.
- Sathyanarayana, S., 2008. Phthalates and children's health. *Curr. Probl. Pediatr. Adolesc. Health Care* 38, 34–49.
- Sathyanarayana, S., Butts, S., Wang, C., Barrett, E., Nguyen, R., Schwartz, S.M., Haaland, W., Swan, S.H., 2017. Early prenatal phthalate exposure, sex steroid hormones, and

- birth outcomes. *J. Clin. Endocrinol. Metab.* 102, 1870–1878.
- Savitz, D.A., Janevic, T.M., Engel, S.M., Kaufman, J.S., Herring, A.H., 2008. Ethnicity and gestational diabetes in New York City, 1995–2003. *BJOG* 115, 969–978.
- Schettler, T., 2006. Human exposure to phthalates via consumer products. *Int. J. Androl.* 29, 134–139 (discussion 181–135).
- Serrano, S.E., Braun, J., Trasande, L., Dills, R., Sathyanarayana, S., 2014. Phthalates and diet: a review of the food monitoring and epidemiology data. *Environ. Health* 13, 43.
- Shapiro, G.D., Dodds, L., Arbuckle, T.E., Ashley-Martin, J., Fraser, W., Fisher, M., Taback, S., Keely, E., Bouchard, M.F., Monnier, P., Dallaire, R., Morisset, A., Ettinger, A.S., 2015. Exposure to phthalates, bisphenol A and metals in pregnancy and the association with impaired glucose tolerance and gestational diabetes mellitus: the MIREC study. *Environ. Int.* 83, 63–71.
- Silva, M.J., Samandar, E., Preau Jr., J.L., Reidy, J.A., Needham, L.L., Calafat, A.M., 2007. Quantification of 22 phthalate metabolites in human urine. *J. Chromatogr. B Anal. Technol. Biomed. Life Sci.* 860, 106–112.
- Simmons, D., Devers, M.C., Wolmarans, L., Johnson, E., 2009. Difficulties in the use of risk factors to screen for gestational diabetes mellitus. *Diabetes Care* 32, e8.
- Song, Y., Chou Elizabeth, L., Baecker, A., You Nai-Chieh, Y., Song, Y., Sun, Q., Liu, S., 2015. Endocrine-disrupting chemicals, risk of type 2 diabetes, and diabetes-related metabolic traits: a systematic review and meta-analysis. *J. Diabetes* 8, 516–532.
- Srinivasan, C., Khan, A.I., Balaji, V., Selvaraj, J., Balasubramanian, K., 2011. Diethyl hexyl phthalate-induced changes in insulin signaling molecules and the protective role of antioxidant vitamins in gastrocnemius muscle of adult male rat. *Toxicol. Appl. Pharmacol.* 257, 155–164.
- Stahlhut, R.W., van Wijngaarden, E., Dye, T.D., Cook, S., Swan, S.H., 2007. Concentrations of urinary phthalate metabolites are associated with increased waist circumference and insulin resistance in adult US males. *Environ. Health Perspect.* 115, 876–882.
- Stumvoll, M., Haring, H., 2002. The peroxisome proliferator-activated receptor-gamma2 Pro12Ala polymorphism. *Diabetes* 51, 2341–2347.
- Swan, S.H., the T.S.T, Sathyanarayana, S., Barrett, E.S., Janssen, S., Liu, F., Nguyen, R.H.N., Redmon, J.B., 2015. First trimester phthalate exposure and anogenital distance in newborns. *Hum. Reprod.* 30, 963–972.
- The HAPO, 2008. Study cooperative research group hyperglycemia and adverse pregnancy outcomes. *N. Engl. J. Med.* 358, 1991–2002.
- Thorpe, L.E., Berger, D., Ellis, J.A., Bettgowda, V.R., Brown, G., Matte, T., Bassett, M., Frieden, T.R., 2005. Trends and racial/ethnic disparities in gestational diabetes among pregnant women in New York City, 1990–2001. *Am. J. Public Health* 95, 1536–1539.
- Tordjiman, K., Standley, K.N., Bernal-Mizrachi, C., Leone, T.C., Coleman, T., Kelly, D.P., Semenkovich, C.F., 2002. PPARalpha suppresses insulin secretion and induces UCP2 in insulinoma cells. *J. Lipid Res.* 43, 936–943.
- Torloni, M.R., Betrán, A.P., Horta, B.L., Nakamura, M.U., Atallah, A.N., Moron, A.F., Valente, O., 2009. Prepregnancy BMI and the risk of gestational diabetes: a systematic review of the literature with meta-analysis. *Obes. Rev.* 10, 194–203.
- Toulis, K.A., Goulis, D.G., Kolibianakis, E.M., Venetis, C.A., Tarlatzis, B.C., Papadimas, I., 2009. Risk of gestational diabetes mellitus in women with polycystic ovary syndrome: a systematic review and a meta-analysis. *Fertil. Steril.* 92, 667–677.
- Valvi, D., Monfort, N., Ventura, R., Casas, M., Casas, L., Sunyer, J., Vrijheid, M., 2015. Variability and predictors of urinary phthalate metabolites in Spanish pregnant women. *Int. J. Hyg. Environ. Health* 218, 220–231.
- Vandorsten, J.P., Dodson, W.C., Espeland, M.A., Grobman, W.A., Guise, J.M., Mercer, B.M., Minkoff, H.L., Poindexter, B., Prosser, L.A., Sawaya, G.F., 2012. NIH consensus development conference: diagnosing gestational diabetes mellitus. *NIH Consens. State Sci. Statements* 29, 1–31.
- Vigouroux, C., Fajas, L., Khallouf, E., Meier, M., 1998. Human peroxisome proliferator-activated receptor-gamma2: genetic mapping, identification of a variant in the coding sequence, and exclusion as the gene responsible for lipotrophic diabetes. *Diabetes* 47, 490.
- Viswanathan, M.P., Mullainadhan, V., Chinnaiyan, M., Karundevi, B., 2017. Effects of DEHP and its metabolite MEHP on insulin signalling and proteins involved in GLUT4 translocation in cultured L6 myotubes. *Toxicology* 386, 60–71.
- Wendland, E.M., Pinto, M.E., Duncan, B.B., Belizán, J.M., Schmidt, M.I., 2008. Cigarette smoking and risk of gestational diabetes: a systematic review of observational studies. *BMC Pregnancy Childbirth* 8, 53.
- Winkler, G., Cseh, K., Baranyi, É., Melczer, Z., Speer, G., Hajós, P., Salamon, F., Turi, Z., Kovács, M., Vargha, P., Karádi, I., 2002. Tumor necrosis factor system in insulin resistance in gestational diabetes. *Diabetes Res. Clin. Pract.* 56, 93–99.
- Zhang, C., Ning, Y., 2011. Effect of dietary and lifestyle factors on the risk of gestational diabetes: review of epidemiologic evidence. *Am. J. Clin. Nutr.* 94, 1975S–1979S.